Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen BiotechBOM:531146 -0.82%61 PS Ratio is 1.65 as of Aug. 16, 2026, which is 63% below its 10-year median of 4.46. GuruFocus rates BOM:531146 with a GF Score™ of 61/100 and a GF Value™ of ₹512.38 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, Medicamen Biotech ranks better than 61.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medicamen Biotech's share price is ₹240.75.
Medicamen Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹145.63. Hence, Medicamen Biotech's PS Ratio for today is 1.65.
Good Sign:
Medicamen Biotech Ltd stock PS Ratio (=1.65) is close to 10-year low of 1.56.
The historical rank and industry rank for Medicamen Biotech's PS Ratio or its related term are showing as below:
BOM:531146'
s PS Ratio Range Over the Past 10 Years
Min: 1.56 Med: 4.46 Max: 11.5
Current: 1.65
During the past 13 years, Medicamen Biotech's highest PS Ratio was 11.50. The lowest was 1.56. And the median was 4.46.
BOM:531146's PS Ratio is ranked better than 61.45% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs BOM:531146: 1.65
During the past 12 months, the average Revenue per Share Growth Rate of Medicamen Biotech was 14.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 6.40% per year.
During the past 13 years, Medicamen Biotech's highest 3-Year average Revenue per Share Growth Rate was 16.80% per year. The lowest was -18.50% per year. And the median was 3.45% per year.
Medicamen Biotech (BOM:531146) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medicamen Biotech PS Ratio Related Terms
Medicamen Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for Medicamen Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Biotech PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medicamen Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medicamen Biotech's Share Price of today is ₹240.75. Medicamen Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹145.63.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medicamen Biotech (BOM:531146) has a PS Ratio of 1.65 as of Aug. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medicamen Biotech and its competitors. This is 63% below median its historical median of 4.46. Over the past decade, Medicamen Biotech's PS Ratio has ranged from 1.56 to 11.50. According to the industry distribution chart, Medicamen Biotech ranks #367 out of 952 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Medicamen Biotech's PS Ratio too high?
Medicamen Biotech's current PS Ratio of 1.65 is 63% below median its 10-year median of 4.46. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 11.50. The Drug Manufacturers industry median PS Ratio is 2.31. Medicamen Biotech's value of 1.65 is 28.6% below this industry median. Based on the distribution chart, Medicamen Biotech ranks #367 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medicamen Biotech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicamen Biotech's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicamen Biotech ranks #367 out of 952 companies for PS Ratio. This puts Medicamen Biotech in the upper half of its industry. The industry median PS Ratio is 2.31. Medicamen Biotech's value of 1.65 is 28.6% below this benchmark. Historically, Medicamen Biotech's own PS Ratio has ranged from 1.56 to 11.50 over the past decade. While the company's 10-year median is 4.46 vs. the industry median of 2.31, Medicamen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicamen Biotech's current PS Ratio of 1.65 is 28.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medicamen Biotech and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Biotech's current PS Ratio is 1.65, which is 63% below median its own 10-year median of 4.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicamen Biotech (BOM:531146) is currently considered Possible Value Trap. The stock's GF Value™ is ₹512.38, compared to a current price of ₹240.75 — trading 53% below its estimated fair value. The current PS Ratio is 1.65, which is 63% below median its 10-year median of 4.46 and 28.6% below the Drug Manufacturers industry median of 2.31. Medicamen Biotech's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medicamen Biotech (BOM:531146), the current PS Ratio is 1.65 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicamen Biotech (BOM:531146) Overvalued in 2026?
Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued.
The current stock price of ₹240.75 is trading 53% below its estimated GF Value™ of ₹512.38.
GuruFocus considers Medicamen Biotech to be Possible Value Trap.
Key valuation signals for BOM:531146:
PS Ratio: 1.65 (63% below median its 10-year median of 4.46)
GF Value™: ₹512.38 vs. price of ₹240.75 (53% below fair value)
Industry Position: 28.6% below the Drug Manufacturers median (#367 of 952)
No single metric tells the full story. See the BOM:531146 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
61GF Score
Get the complete analysis for BOM:531146
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531146 has been successfully added to your 
